Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report.

Abstract

Mitotane provided serious side effects and low doses seemed to be tolerated. Determination of mitotane concentration in plasma is recommended. We report the case of toxic plasma levels with low doses of mitotane in a 47-year-old man with adrenocortical cancer.

• Authors: Nadia Jebabli, Emna Gaïes, Hanen Eljebari, Rim Charfi, Mohamed Lakhal, Anis Klouz, Issam Salouage, Sameh Trabelsi
• Journal: Therapie (Therapie) 2015 Nov-Dec Vol. 70 Issue 6 Pg. 545-6 ISSN: 0040-5957 [Print] France
• PMID: 26242497 (Publication Type: Case Reports, Letter)
• Copyright: © 2015 Société Française de Pharmacologie et de Thérapeutique.

Chemical References

• Antineoplastic Agents, Hormonal
• Mitotane

Topics

• Adrenal Cortex Neoplasms (blood, drug therapy)
• Antineoplastic Agents, Hormonal (administration & dosage, adverse effects, blood, therapeutic use)
• Asthenia (chemically induced)
• Carcinoma (blood, drug therapy)
• Chromatography, High Pressure Liquid
• Dose-Response Relationship, Drug
• Drug Monitoring
• Humans
• Male
• Middle Aged
• Mitotane (administration & dosage, adverse effects, blood, therapeutic use)
• Nausea (chemically induced)
• Vomiting (chemically induced)